Company news
Immutep Ltd (ASX:IMM) news
Immutep Ltd news releases on 6ix. Latest, May 4, 2022: New & significant data from AIPAC phase 2b trial in MBC
Press releases — page 4
New & significant data from AIPAC phase 2b trial in MBC
May 4, 2022
Immutep to announce new TACTI-002 data at ASCO 2022
April 27, 2022
Efti with Keytruda shows encouraging activity in lung cancer
March 29, 2022
Immutep announces publication of ELCC 2022 abstract
March 23, 2022
Japanese patent granted for LAG-3 antibody LAG525
March 18, 2022
Immutep receives FDA feedback for Efti development in MBC
March 9, 2022
Australian Patent Granted for Efti with PD-1 Inhibitors
February 11, 2022
Immutep Advances IMP761 Manufacturing
December 15, 2021
Good safety reported from 1st five patients in INSIGHT-003
December 1, 2021
Phase II TACTI-002 trial recruitment successfully completed
November 18, 2021
Immutep Global Webcast Slides to Discuss Clinical Results
November 16, 2021
Immutep announces publication of SITC 2021 posters
November 14, 2021
Immutep announces publication of SITC 2021 abstracts
November 9, 2021
Immutep granted Chinese Patent for eftilagimod alpha
November 2, 2021
Immutep receives EMA scientific advice for Phase 3 in MBC
October 28, 2021
Immutep Quarterly Activities Report & Appendix 4C
October 27, 2021
Immutep Receives A$3.4 million R&D French Tax Incentive
September 28, 2021
Recruitment of patients completed for Part B of TACTI-002
September 1, 2021
Immuteps partner, EOC Pharma, expands efti trial pipeline
August 30, 2021
Chinese patent granted for anti-LAG-3 antibody LAG525
August 26, 2021
INSIGHT-003 investigator-initiated trial - 1st patient dosed
August 4, 2021
Completion of Placement - Tranche 2
July 29, 2021
Completion of Share Purchase Plan
July 20, 2021
US FDA & IRB approves start of ph2b head & neck cancer trial
July 5, 2021
Efti to be evaluated in new triple combination therapy trial
June 21, 2021
Immutep secures commitments for A$60 million in a Placement
June 20, 2021
Immutep global webcast slides
June 9, 2021
Immutep Reveals a New anti-LAG-3 Research Program
June 7, 2021
Immutep Reports Positive Data from its TACTI-002 ph 2 trial
June 4, 2021
Immutep granted European patent for its LAG-3 candidate Efti
June 2, 2021
Immutep enters New Collaboration with Merck KGaA for Efti
May 31, 2021
Immutep granted Chinese patent for its LAG-3 candidate Efti
May 26, 2021
Operational Update
May 7, 2021
TACTI-002 & INSIGHT-004 data to be presented at ASCO
April 28, 2021
Immutep receives A$1,155,055 R&D Tax Incentive
April 16, 2021
Immutep achieves Fast Track designation for Efti from US FDA
April 7, 2021
Immutep announces European Patent Grant for LAG525
April 6, 2021
Immutep collaborates with MSD for phase 2b head & neck trial
March 15, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Immutep secures second US patent grant for eftilagimod alpha
March 9, 2021
Phase II study for eftilagimod alpha in COVID-19 advances
January 26, 2021
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
January 21, 2021
Recruitment of head & neck cancer patients completed for ph2
January 6, 2021
Immutep granted US patent for eftilagimod alpha with a PD-1
December 29, 2020
Immutep Upscales Efti Manufacturing
December 16, 2020
Immuteps partner EOC pharma to start Ph II trial in MBC
December 9, 2020
Proposed issue of Securities - IMM
November 18, 2020
Pause in Trading
November 17, 2020
Encouraging Phase II TACTI-002 data reported at SITC 2020
November 9, 2020
Immutep Announces Australian Patent Grant for IMP701
November 8, 2020